Arcellxの空売り状況は、投資家がArcellxの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Arcellx (NASDAQ:ACLX) 株価情報, 空売り情報

Arcellx

Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.

Arcellx Inc

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is trading 2.2% higher in pre-market on Thursday following upbeat analyst calls on the stock as well as news over new EV taxes to finance road repairs which could impact its rivals.
What Happened: Today, Wedbush Securities analyst Dan Ives <a href="https://www.benzinga.com/25/02/43682491/elon-musks-doge-dedication-sparks-tesla-brand-deterioration-as-ev-maker-drops-20-after-trump-inauguration-dan-ives-says-bark-way-worse-than-the-bite">maintained his bullish stance</a> on Tesla and his $550 price target on the stock, despite concerns over Musk&#8217;s dedication to DOGE, causing potential brand deterioration.
Similarly, on Wednesday, Analyst Mickey Legg from Benchmark Equity placed a &#8216;Buy&#8217; rating and a $475 price target on the stock. He identified major growth drivers for Tesla in the fields of <a href="https://www.benzinga.com/trading-ideas/movers/25/02/43675344/tesla-jumps-as-analyst-highlights-growth-in-evs-ai-robotics">autonomous vehicles, robotics, and energy generation </a>and storage. 
In another development, the U.S. Senate Republicans, on Wednesday, proposed two bills to remove the country&#8217;s $7,500 electric vehicle tax credit and introduce a new $1,000 tax on EVs to support road maintenance. This is likely to come as a blow to Tesla rivals like General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) and Ford Motor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) who have been <a href="https://www.benzinga.com/markets/25/02/43648415/tesla-rivals-call-for-gradual-elimination-of-ev-tax-credits-many-of-those-jobs-will-be-at-risk">pushing for a gradual phase out </a>of the EV tax credits. Tesla has always maintained its stance on the elimination of EV subsidies.
SEE ALSO: <a href="https://www.benzinga.com/25/02/43681521/cathie-wood-dumps-more-palantir-amid-stocks-red-hot-rally-robinhood-also-gets-the-chop-ark-adds-amd-and-tsmc-stock">Cathie Wood Dumps More Palantir Amid Stock&#8217;s Red-Hot Rally, Robinhood Also Gets The Chop — Ark Adds AMD And TSMC Stock</a>
Why It Matters: Tesla&#8217;s growth prospects have been a topic of discussion, especially with CEO Elon Musk&#8217;s involvement in various ventures. 
Despite regulatory uncertainty and increasing EV competition putting downward pressure on vehicle pricing, analyst Mickey Legg is confident that Tesla&#8217;s product range will help mitigate these challenges. With $36.5 billion in cash and investments, the Elon Musk-led company is well-placed to pursue significant expansion possibilities, as per Legg. 
These events highlight the dynamic nature of Tesla&#8217;s operations and the potential impact of external factors on its growth trajectory.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/markets/25/02/43686104/mitch-mcconnell-criticizes-trumps-tariff-plans-warns-of-potential-price-hike-big-lingering-concerns-for-american-industry-and-workers">Mitch McConnell Criticizes Trump&#8217;s Tariff Plans, Warns Of Potential Price Hike: &#8216;Big, Lingering Concerns For American Industry And Workers&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

Tech

TSLA

Tesla Stock Climbs Over 2% In Thursday Pre-Market: What's Going On?

Chardan Capital analyst Geulah Livshits maintains CRISPR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) with a Buy and lowers the price target from $94 to $84.

News

Price Target

Analyst Ratings

CRSP

Chardan Capital Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $84

Jefferies analyst Omar Nokta maintains Scorpio Tankers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STNG#NYSE">STNG</a>) with a Buy and maintains $75 price target.

STNG

Jefferies Maintains Buy on Scorpio Tankers, Maintains $75 Price Target

Piper Sandler analyst Joseph Catanzaro initiates coverage on Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Overweight rating and announces Price Target of $84.

Initiation

MRUS

Piper Sandler Initiates Coverage On Merus with Overweight Rating, Announces Price Target of $84

President Donald Trump has nominated Jonathan Morrison to be administrator of the U.S. auto safety regulator National Highway Traffic Safety Administration (NHTSA) responsible for overseeing safety probes into multiple automakers including Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).
What Happened: The nomination was referred to Committee on Commerce, Science, and Transportation, the record show, following which it would be sent for a full Senate vote. 
According to Morrison&#8217;s LinkedIn profile, he is currently an Apple employee who previously served as chief counsel of NHTSA during Trump&#8217;s previous term. He was also formerly the Director of Legal &amp; Regulatory Affairs of the California New Car Dealers Association.
If sworn in, Morrison will oversee the agency that probes automakers, including Elon Musk&#8217;s Tesla, over safety concerns. 
Last month the Department of Transportation Secretary Sean Duffy <a href="https://www.benzinga.com/markets/equities/25/01/43020202/trumps-dot-pick-assures-ongoing-tesla-fsd-investigation-and-rigorous-oversight-of-boeing">committed to allowing the NHTSA to proceed </a>with its investigation into Tesla's Full Self-Driving (FSD) software. 
"I commit to this committee and to you that I will let NHTSA do their investigation," Duffy said when asked if Musk&#8217;s proximity to President Trump will impact ongoing investigations. Musk is leading the department of government efficiency under the Trump administration. 
Why It Matters: In January, NHTSA opened a probe&nbsp;<a href="https://www.benzinga.com/25/01/42840097/nhtsa-opens-probe-into-26-million-tesla-vehicles-after-complaint-of-crash-involving-actually-smart-summon-feature" target="_blank" rel="noreferrer noopener">into about 2.6 million Tesla vehicles</a>&nbsp;equipped with the company's full self-driving driver assistance technology following a complaint alleging that the use of its "Actually Smart Summon" feature led to a crash.
Actually Smart Summon refers to a feature that allows a user to remotely move the vehicle towards themselves or to another nearby location such as a parking lot through the company's phone app.
In October, NHTSA opened an investigation into<a href="https://www.benzinga.com/news/24/10/41398764/nhtsa-opens-probe-into-2-4m-tesla-vehicles-after-reports-of-4-crashes-with-fsd-involved" target="_blank" rel="noreferrer noopener">&nbsp;2.4 million Tesla vehicles</a>&nbsp;following reports of four crashes where FSD was engaged. 
The regulator then said that it had identified four crash reports in which a Tesla experienced a crash after entering an area of &#8220;reduced roadway visibility&#8221; with FSD engaged.&nbsp;The reduced visibility, the regulator said, was caused by sun glare, fog, or airborne dust.
In one of the crashes, the vehicle struck and killed a pedestrian, the regulator added.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43684382/tesla-offers-discounts-up-to-6000-on-model-year-2024-cybertrucks-in-inventory" target="_blank" rel="noreferrer noopener">Tesla Hikes Discounts On Cybertrucks By 3X To $6000 As It Looks To Clear 2024 Inventory</a></li>
</ul>
Photo courtesy: Shutterstock

Politics

Trump Nominates Apple Employee To Oversee Safety Probes Multiple Automakers, Including Elon Musk's Tesla

Canaccord Genuity analyst Joseph Vafi maintains IREN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) with a Buy and raises the price target from $17 to $23.

IREN

Canaccord Genuity Maintains Buy on IREN, Raises Price Target to $23

The solution harmonizes data from organizations' most mission-critical applications with data engineering and business analytics capabilities, paving the way for next-level innovation and insights.
SAP today also announced a powerful new agent builder capability, so customers can build and deploy their own AI agents alongside SAP's library of ready-to-deploy Joule agents.

SAP Unveils Business Data Cloud With Databricks; Also Announces New Agent Builder Capability

Telsey Advisory Group analyst Joseph Feldman maintains Kroger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) with a Outperform and raises the price target from $70 to $73.

Telsey Advisory Group Maintains Outperform on Kroger, Raises Price Target to $73

Piper Sandler analyst Alexander Goldfarb downgrades Kite Realty Gr Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRG#NYSE">KRG</a>) from Overweight to Neutral and lowers the price target from $33 to $25.

Downgrades

Piper Sandler Downgrades Kite Realty Gr Trust to Neutral, Lowers Price Target to $25

The partnership will enable Ooredoo to expand its MENA footprint of hyperscale and AI data centre infrastructure, combining the strength of the company's local development and operational track record with Iron Mountain's global operating expertise.
 &nbsp;

Iron Mountain To Take Minority Equity Stake In Ooredoo's Data Centre Company MENA Digital Hub, No Terms Disclosed

Telsey Advisory Group analyst Dana Telsey maintains Birkenstock Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>) with a Outperform and maintains $70 price target.

BIRK

Telsey Advisory Group Maintains Outperform on Birkenstock Holding, Maintains $70 Price Target

Supported by today's announcement that Forschungszentrum Jülich (FZJ) is the first high-performance computing (HPC) center in the world to purchase a D-Wave Advantage quantum system, D-Wave expects the new systems offering to drive advanced research and new discoveries in areas such as artificial intelligence (AI) and quantum simulation.
The Company also announced the new "Quantum Uplift" program to address the growing number of customers expressing disappointment with competitor quantum systems that are incapable of solving problems of practical value and lack reliable uptime and availability.&nbsp;

QBTS

D-Wave Quantum Reveals On-Premises Systems Offering; Also Unveils Quantum Uplift Program

Non-Executive Board Chair Nancy E. Cooper will remain on the Brunswick Board and current Board member David E. Everitt will assume the role of Lead Independent Director.
Foulkes was appointed Chief Executive Officer and a member of the Board of Brunswick Corporation in January 2019.

Management

Brunswick Board Elects CEO David M. Foulkes As Chairman Of Board, Effective March 1

Seaport Global analyst Tom Curran downgrades Aspen Aerogels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) from Buy to Neutral.

ASPN

Seaport Global Downgrades Aspen Aerogels to Neutral

Shares of AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) rose sharply in today's pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued first-quarter revenue guidance <a href="https://www.benzinga.com/news/earnings/25/02/43676556/applovin-stock-soars-on-q4-earnings-revenue-beat-eps-beat-strong-guidance-and-more">above estimates</a>.
Applovin reported fourth-quarter revenue of $1.37 billion, beating analyst estimates of $1.26 billion, according to Benzinga Pro. The company reported fourth-quarter earnings of $1.73 per share, beating analyst estimates of $1.25 per share.
AppLovin shares jumped 28.9% to $490.10 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Phoenix Motor Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEV#NASDAQ">PEV</a>) gained 81.2% to $0.4570 in pre-market trading after the company said third-quarter revenue jumped 1,557% year-over-year to $4.77 million.</li>
<li>Tivic Health Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) rose 42% to $0.9937 in pre-market trading. Tivic Health Systems shares jumped 198% on Wednesday after the company announced it acquired the exclusive license rights from Statera Biopharma for its Phase III TLR5 agonist entolimod treatment of acute radiation syndrome.</li>
<li>Avinger, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) shares jumped 45.6% to $0.6701 in pre-market trading.</li>
<li>MGO Global, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGOL#NASDAQ">MGOL</a>) gained 38.5% to $0.6326 in pre-market trading after dipping 24% on Wednesday.</li>
<li>ProPhase Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) gained 26% to $0.3535 in pre-market following a 7% gain in the previous session.</li>
<li>Dutch Bros Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) shares climbed 24.6% to $80.72 in pre-market trading following better-than-expected fourth-quarter financial results.</li>
<li>Twin Disc, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWIN#NASDAQ">TWIN</a>) gained 19.4% to $11.99 in pre-market trading after dipping 10% on Wednesday.</li>
<li>Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) gained 15.6% to $64.72 in pre-market trading after the company reported better-than-expected quarterly financial results.</li>
<li>CEVA, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CEVA#NYSE">CEVA</a>) gained 8.5% to $34.41 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Aspen Aerogels, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) shares fell 30.6% to $8.15 in pre-market trading after the company issued first-quarter guidance below estimates.</li>
<li>The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) dipped 27% to $89.34 in pre-market trading after the company reported worse-than-expected quarterly revenue results.</li>
<li>Omega Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMGA#NASDAQ">OMGA</a>) fell 24.6% to $0.1960 in today's pre-market trading after surging 35% on Wednesday. Omega Therapeutics' restructuring committee recently approved a workforce reduction of up to 17 employees for cost-reduction amid a Chapter 11 case and potential asset sale.</li>
<li>NKGen Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) shares fell 24.4% to $0.6363 in pre-market trading. NKGen Biotech shares jumped 122% on Wednesday after the company received FDA Fast Track designation for Troculeucel for the treatment of moderate Alzheimer&#8217;s disease.</li>
<li>Mynaric AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNA#NASDAQ">MYNA</a>) fell 23.7% to $0.4730 in pre-market trading after jumping 134% on Wednesday.</li>
<li>Fastly, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLY#NYSE">FSLY</a>) shares tumbled 20.6% to $8.00 in pre-market trading. Fastly reported a fourth-quarter loss of 3 cents per share, down from earnings of 1 cent per share in the prior year&#8217;s quarter. Quarterly revenue came in at $140.58 million, beating the $138.27 million analyst consensus estimate. Fastly expects first-quarter losses of between 9 cents and 5 cents per share, versus the loss of 1 cent estimate, and revenue in a range of $136 million to $140 million, versus the $137.05 million estimate.</li>
<li>Solaris Resources Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLSR#NYSE">SLSR</a>) declined 18.1% to $3.30 in pre-market trading.</li>
<li>Atai Life Sciences N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) fell 14.5% to $2.1800 in pre-market trading after the company announced the pricing of public offering of common shares.</li>
<li>Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) fell 14.1% to $185.94 in pre-market trading after the company reported fourth-quarter results.</li>
<li>Open Lending Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPRO#NASDAQ">LPRO</a>) shares dipped 13% to $5.02 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43655479/top-3-utilities-stocks-that-may-collapse-in-q1">Top 3 Utilities Stocks That May Collapse In Q1</a></li>
</ul>

ATAI

AVGR

BROS

CEVA

FSLY

HOOD

LPRO

MGOL

MYNA

NKGN

OMGA

PRPH

RDDT

SLSR

TIVC

TWIN

Why AppLovin Shares Are Trading Higher By Around 29%; Here Are 20 Stocks Moving Premarket

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="2">First Quarter 2025 Guidance &nbsp;</td>
</tr>
<tr>
<td>Net Revenue:</td>
<td>Decrease 8.5% to 12.5% QoQ, Flat to Up 4.6% YoY</td>
</tr>
<tr>
<td>Gross Margin:</td>
<td>Around 30.5%, depending on final product mix</td>
</tr>
<tr>
<td>Profit:</td>
<td>9.0 cents to 11.0 cents per diluted ADS, Up 26% to 54% YoY&nbsp;&nbsp;</td>
</tr>
</tbody>
</table>
</figure>

Guidance

HIMX

Himax Technologies Expects Q1 Revenue Growth Of Flat To 4.6% YoY Vs $200.7M Est, EPADS Of $0.09-$0.11 Vs $0.08 Est

TD Securities analyst Andrew Charles maintains Dutch Bros (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) with a Buy and raises the price target from $65 to $89.

TD Securities Maintains Buy on Dutch Bros, Raises Price Target to $89

<h2>Nissan Motor Co., Ltd. ("Nissan") and Honda Motor Co., Ltd. ("Honda") , today agreed to terminate the MOU signed on December 23 last year for consideration of a business integration between the two companies.</h2>
https://global.honda/en/newsroom/news/2025/c250213aeng.html

NSANY

Earlier Nissan, Honda Announced Termination Of MOU For Consideration Of Business Integration

Earnings

Himax Technologies Q4 EPS $0.14 Beats $0.10 Estimate, Sales $237.22M Beat $221.09M Estimate

Needham analyst Scott Berg reiterates Similarweb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMWB#NYSE">SMWB</a>) with a Buy and maintains $14 price target.

Reiteration

SMWB

Needham Reiterates Buy on Similarweb, Maintains $14 Price Target

Barclays analyst Peter Lawson maintained a Buy rating on Arcellx Inc (ACLX – Research Report) today and set a price target of $115.00. The company'...

Barclays Sticks to Their Buy Rating for Arcellx Inc (ACLX)

Canaccord Genuity analyst John Newman maintained a Buy rating on Arcellx Inc (ACLX – Research Report) today and set a price target of $121.00. John...

Positive Outlook for Arcellx Inc. Based on Promising Clinical Trial Results and Superior Safety Profile

William Blair analyst Sami Corwin has maintained their bullish stance on ACLX stock, giving a Buy rating today. Sami Corwin has given his Buy ratin...

Promising Prospects for Anito-cel in Relapsed Multiple Myeloma: Buy Rating Affirmed

UBS analyst Ashwani Verma raised the firm's price target on Arcellx (ACLX) to $114 from $106 and keeps a Buy rating on the shares. UBS believes Arc...

Arcellx price target raised to $114 from $106 at UBS

In a report released yesterday, Judah Frommer from Morgan Stanley maintained a Buy rating on Arcellx Inc (ACLX – Research Report), with a price tar...

Promising Outlook for Arcellx Inc: Anito-cel Therapy Positioned as a Safer Alternative with Strong Market Potential

In a report released today, Richard Newitter from Truist Financial maintained a Buy rating on Arcellx Inc (ACLX – Research Report). The company's s...

Arcellx Inc (ACLX) Gets a Buy from Truist Financial

Oppenheimer laid out five "aspirational" potential takeover targets in biotech heading into the annual JPMorgan Health Care Conference. "We need mo...

Opco lists five potential biotech targets into JPMorgan conference

Viking Therapeutics among potential buyout candidates: Oppenheimer

Arcellx, Inc.: Trying To Build A Better Myeloma Cell Therapy

Baron Health Care Fund Q4 2024 Shareholder Letter

ACLX

AMGN

ARGNF

ARGX

AZNCF

BCAP

BPMC

BROE

EWTX

GILD

GKOS

ISRG

JANX

LEGN

NTRA

NUVL

RDNT

REGN

VKTX

VRTX

Press Releases

Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Arcellx to Participate in Two Upcoming Investor Conferences

Arcellx Provides First Quarter 2024 Financial Results

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

Arcellx Provides Second Quarter 2024 Financial Results and Business Updates

Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study

Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition

Comments

Arcellx

空売り

Arcellx (NASDAQ:ACLX) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル